STEAP proteins: From structure to applications in cancer therapy

Molecular Cancer Research

Volumn 10, Issue 5, 2012, Pages 573-587

  Gomes, Inês M ^a   Maia, Cláudio J ^a   Santos, Cecília R ^a  

^a UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN; PROTEIN 6 TRANSMEMBRANE EPITHELIAL ANTIGEN OF PROSTATE 1; PROTEIN 6 TRANSMEMBRANE EPITHELIAL ANTIGEN OF PROSTATE 2; PROTEIN 6 TRANSMEMBRANE EPITHELIAL ANTIGEN OF PROSTATE 3; PROTEIN 6 TRANSMEMBRANE EPITHELIAL ANTIGEN OF PROSTATE 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

6 TRANSMEMBRANE EPITHELIAL ANTIGEN OF PROSTATE 1 GENE; 6 TRANSMEMBRANE EPITHELIAL ANTIGEN OF PROSTATE 2 GENE; 6 TRANSMEMBRANE EPITHELIAL ANTIGEN OF PROSTATE 3 GENE; 6 TRANSMEMBRANE EPITHELIAL ANTIGEN OF PROSTATE 4 GENE; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL EXPANSION; CELL MEMBRANE; CELL PROLIFERATION; CELL STRAIN HEPG2; CELLULAR DISTRIBUTION; COLON CANCER; DISEASE MARKER; DOWN REGULATION; EWING SARCOMA; GENE; GENE OVEREXPRESSION; GENE STRUCTURE; HUMAN; IMMUNE RESPONSE; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; KIDNEY CANCER; LIVER CELL CARCINOMA; LYMPHOMA; MELANOMA; METABOLIC SYNDROME X; MYELOID LEUKEMIA; NONHUMAN; OSTEOARTHRITIS; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; RNA TRANSLATION; SINGLE NUCLEOTIDE POLYMORPHISM; TESTIS CANCER; TRANS GOLGI NETWORK; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER;

ANTIGENS, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASMS; OXIDOREDUCTASES; PROSTATE;

MAMMALIA;

EID: 84861142181     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-11-0281     Document Type: Review

References (87)

1. Ohgami RS, Campagna DR, McDonald A, Fleming MD. The Steap proteins are metalloreductases. Blood 2006;108:1388-94. (Pubitemid 44232042)
2. Finegold AA, Shatwell KP, Segal AW, Klausner RD, Dancis A. Intra-membrane bis-heme motif for transmembrane electron transport conserved in a yeast iron reductase and the human NADPH oxidase. J Biol Chem 1996;271:31021-4. (Pubitemid 26408536)
3. Ohgami RS, Campagna DR, Greer EL, Antiochos B, McDonald A, Chen J, et al. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet 2005;37: 1264-9. (Pubitemid 41568711)
4. Sanchez-Pulido L, Rojas AM, Valencia A, Martinez-A C, Andrade MA. ACRATA: a novel electron transfer domain associated to apoptosis and cancer. BMC Cancer 2004;4:98.
5. Lambe T, Simpson RJ, Dawson S, Bouriez-Jones T, Crockford TL, Lepherd M, et al. Identification of a Steap3 endosomal targeting motif essential for normal iron metabolism. Blood 2009;113:1805-8.
6. Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A 1999;96:14523-8. (Pubitemid 30000683)
7. Korkmaz KS, Elbi C, Korkmaz CG, Loda M, Hager GL, Saatcioglu F. Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer. J Biol Chem 2002;277:36689-96.
8. Porkka KP, Helenius MA, Visakorpi T. Cloning and characterization of a novel six-transmembrane protein STEAP2, expressed in normal and malignant prostate. Lab Invest 2002;82:1573-82. (Pubitemid 35332916)
9. Kent WJ. BLAT-the BLAST-like alignment tool. Genome Res 2002;12:656-64.
10. Passer BJ, Nancy-Portebois V, Amzallag N, Prieur S, Cans C, Roborel de Climens A, et al. The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interactswith Nix and the Myt1 kinase. Proc Natl Acad Sci U S A 2003;100:2284-9. (Pubitemid 36297491)
11. Korkmaz CG, Korkmaz KS, Kurys P, Elbi C, Wang L, Klokk TI, et al. Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer. Oncogene 2005;24:4934-45. (Pubitemid 41129097)
12. Maia CJB, Socorro S, Schmitt F, Santos CR. STEAP1 is over-expressed in breast cancer and down-regulated by 17beta-estradiol in MCF-7 cells and in the rat mammary gland. Endocrine 2008;34:108-16.
13. Amzallag N, Passer BJ, Allanic D, Segura E, Théry C, Goud B, et al. TSAP6 facilitates the secretion of translationally controlled tumor protein/histamine-releasing factor via a nonclassical pathway. J Biol Chem 2004;279:46104-12. (Pubitemid 39491604)
14. Zhang C-M, Chi X, Wang B, Zhang M, Ni Y-H, Chen R-H, et al. Downregulation of STEAP4, a highly-expressed TNF-alpha-inducible gene in adipose tissue, is associated with obesity in humans. Acta Pharmacol Sin 2008;29:587-92. (Pubitemid 351601451)
15. Challita-Eid PM, Morrison K, Etessami S, An Z, Morrison KJ, Perez-Villar JJ, et al. Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. Cancer Res 2007;67:5798-805. (Pubitemid 46985013)
16. Lalani el-N, Laniado ME, Abel PD. Molecular and cellular biology of prostate cancer. Cancer Metastasis Rev 1997;16:29-66.
17. Smith P, Rhodes NP, Shortland AP, Fraser SP, Djamgoz MBA, Ke Y, et al. Sodium channel protein expression enhances the invasiveness of rat and human prostate cancer cells. FEBS Lett 1998;423:19-24. (Pubitemid 28098571)
18. Bennett ES, Smith BA, Harper JM. Voltage-gated Na+ channels confer invasive properties on human prostate cancer cells. Pflugers Arch 2004;447:908-14. (Pubitemid 38372925)
19. Laniado ME, Lalani E-N, Fraser SP, Grimes JA, Bhangal G, Djamgoz MBA, et al.Expression and functional analysis of voltage-activated Na+ channels in human prostate cancer cell lines and their contribution to invasion in vitro. Am J Pathol 1997;150:1213-21. (Pubitemid 27152640)
20. Yildirim S, Fraser SP, Diss JKJ, Altun S, Patel A, Djamgoz MBA. Pathobiology of prostate cancer: voltage-gated sodium channel expression and metastatic potential. IUFS J Biol 2009;68:1-17.
21. Laniado ME, Fraser SP, Djamgoz MBA. Voltage-gated K(+) channel activity in human prostate cancer cell lines of markedly different metastatic potential: distinguishing characteristics of PC-3 and LNCaP cells. Prostate 2001;46:262-74. (Pubitemid 32186908)
22. Prevarskaya N, Skryma R, Bidaux G, Flourakis M, Shuba Y. Ion channels in death and differentiation of prostate cancer cells. Cell Death Differ 2007;14:1295-304. (Pubitemid 46965260)
23. Prevarskaya N, Skryma R, Shuba Y. Ca2+ homeostasis in apoptotic resistance of prostate cancer cells. Biochem Biophys Res Commun 2004;322:1326-35. (Pubitemid 39164661)
24. Skryma RN, Prevarskaya NB, Dufy-Barbe L, Odessa MF, Audin J, Dufy B. Potassium conductance in the androgen-sensitive prostate cancer cell line, LNCaP: involvement in cell proliferation. Prostate 1997; 33:112-22. (Pubitemid 27415535)
25. Pan YZ, Li Y, Guo LR, Zhao YY, Zhao XJ. [Influence of expression of six transmembrane epithelial antigen of the prostate-1 on intracellular reactive oxygen species level and cell growth: an in vitro experiment]. Zhonghua Yi Xue Za Zhi 2008;88:641-4.
26. Knutson MD. Steap proteins: implications for iron and copper metabolism. Nutr Rev 2007;65:335-40. (Pubitemid 351804358)
27. Wang L, Jin Y, Arnoldussen YJ, Jonson I, Qu S, Maelandsmo GM, et al. STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer. Cancer Res 2010;70:5818-28.
28. Ohgami RS, Campagna DR, Antiochos B, Wood EB, Sharp JJ, Barker JE, et al. nm1054: a spontaneous, recessive, hypochromic, microcytic anemia mutation in the mouse. Blood 2005;106:3625-31. (Pubitemid 41609203)
29. Aerbajinai W, Giattina M, Lee YT, Raffeld M, Miller JL. The proapoptotic factor Nix is coexpressed with Bcl-xL during terminal erythroid differentiation. Blood 2003;102:712-7. (Pubitemid 36841996)
30. Liu F, Stanton JJ, Wu Z, Piwnica-Worms H. The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. Mol Cell Biol 1997;17:571-83. (Pubitemid 27044356)
31. Schweers RL, Zhang J, Randall MS, Loyd MR, Li W, Dorsey FC, et al. NIX is required for programmed mitochondrial clearance during reticulocyte maturation. Proc Natl Acad Sci U S A 2007; 104:19500-5.
32. Wells NJ, Watanabe N, Tokusumi T, Jiang W, Verdecia MA, Hunter T. The C-terminal domain of the Cdc2 inhibitory kinase Myt1 interacts with Cdc2 complexes and is required for inhibition of G(2)/M progression. J Cell Sci 1999;112:3361-71. (Pubitemid 29507216)
33. Yussman MG, Toyokawa T, Odley A, Lynch RA, Wu GY, Colbert MC, et al. Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med 2002;8:725-30. (Pubitemid 34778726)
34. Gachet Y, Tournier S, Lee M, Lazaris-Karatzas A, Poulton T, Bommer U-A. The growth-related, translationally controlled protein P23 has properties of a tubulin binding protein and associates transiently with microtubules during the cell cycle. J Cell Sci 1999;112:1257-71. (Pubitemid 29218914)
35. Tuynder M, Susini L, Prieur S, Besse S, Fiucci G, Amson R, et al. Biological models and genes of tumor reversion: cellular reprogramming through tpt1/TCTP and SIAH-1. Proc Natl Acad Sci U S A 2002;99:14976-81. (Pubitemid 35334595)
36. Li F, Zhang D, Fujise K. Characterization of fortilin, a novel antiapoptotic protein. J Biol Chem 2001;276:47542-9.
37. MacDonald SM, Bhisutthibhan J, Shapiro TA, Rogerson SJ, Taylor TE, Tembo M, et al. Immune mimicry in malaria: Plasmodium falciparum secretes a functional histamine-releasing factor homolog in vitro and in vivo. Proc Natl Acad Sci U S A 2001;98:10829-32. (Pubitemid 32878705)
38. Rao KVN, Chen L, Gnanasekar M, Ramaswamy K. Cloning and characterization of a calcium-binding, histamine-releasing protein from Schistosoma mansoni. J Biol Chem 2002;277:31207-13. (Pubitemid 34970827)
39. Théry C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol 1999;147:599-610. (Pubitemid 29523465)
40. Lespagnol A, Duflaut D, Beekman C, Blanc L, Fiucci G, Marine JC, et al. Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice. Cell Death Differ 2008;15:1723-33.
41. Arner P, Stenson BM, Dungner E, Näslund E, Hoffstedt J, Ryden M, et al. Expression of six transmembrane protein of prostate 2 in human adipose tissue associates with adiposity and insulin resistance. J Clin Endocrinol Metab 2008;93:2249-54. (Pubitemid 351831543)
42. Chen X, Zhu C, Ji C, Zhao Y, Zhang C, Chen F, et al. STEAP4, a gene associated with insulin sensitivity, is regulated by several adipokines in human adipocytes. Int J Mol Med 2010;25:361-7.
43. Inoue A, Matsumoto I, Tanaka Y, Iwanami K, Kanamori A, Ochiai N, et al. Tumor necrosis factor alpha-induced adipose-related protein expression in experimental arthritis and in rheumatoid arthritis.Arthritis Res Ther 2009;11:R118.
44. Qin D-N, Kou C-Z, Ni Y-H, Zhang C-M, Zhu J-G, Zhu C, et al. Monoclonal antibody to the six-transmembrane epithelial antigen of prostate 4 promotes apoptosis and inhibits proliferation and glucose uptake in human adipocytes. Int J Mol Med 2010;26:803-11.
45. Tamura T, Chiba J. STEAP4 regulates focal adhesion kinase activation and CpG motifs within STEAP4 promoter region are frequently methylated in DU145, human androgen-independent prostate cancer cells. Int J Mol Med 2009;24:599-604.
46. Fasshauer M, Klein J, Krahlisch S, Lössner U, Klier M, Blüher M, et al. GH is a positive regulator of tumor necrosis factor alpha-induced adipose related protein in 3T3-L1 adipocytes. J Endocrinol 2003; 178:523-31. (Pubitemid 37220178)
47. Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Chambaut-Guérin A-M, et al. Interleukin-6 is a positive regulator of tumor necrosis factor alpha-induced adipose-related protein in 3T3-L1 adipocytes. FEBS Lett 2004;560:153-7. (Pubitemid 38264310)
48. Kralisch S, Sommer G, Weise S, Lipfert J, Lossner U, Kamprad M, et al. Interleukin-1beta is a positive regulator of TIARP/STAMP2 gene and protein expression in adipocytes in vitro. FEBS Lett 2009;583:1196-200.
49. Moldes M, Lasnier F, Gauthereau X, Klein C, Pairault J, Fève B, et al. Tumor necrosis factor-alpha-induced adipose-related protein (TIARP), a cell-surface protein that is highly induced by tumor necrosis factor-alpha and adipose conversion. J Biol Chem 2001;276:33938-46.
50. Ramadoss P, Chiappini F, Bilban M, Hollenberg AN. Regulation of hepatic six transmembrane epithelial antigen of prostate 4 (STEAP4) expression by STAT3 and CCAAT/enhancer-binding protein alpha. J Biol Chem 2010;285:16453-66.
51. Wellen KE, Fucho R, Gregor MF, Furuhashi M, Morgan C, Lindstad T, et al. Coordinated regulation of nutrient and inflammatory responses by STAMP2 is essential for metabolic homeostasis. Cell 2007; 129:537-48. (Pubitemid 46660973)
52. Eriksson JW. Metabolic stress in insulin's target cells leads to ROS accumulation - a hypothetical common pathway causing insulin resistance. FEBS Lett 2007;581:3734-42. (Pubitemid 47086315)
53. Krieger-Brauer HI, Kather H. Human fat cells possess a plasma membrane-bound H2O2-generating system that is activated by insulin via a mechanism bypassing the receptor kinase. J Clin Invest 1992;89:1006-13.
54. Mukherjee SP, Lynn WS. Reduced nicotinamide adenine dinucleotide phosphate oxidase in adipocyte plasma membrane and its activation by insulin. Possible role in the hormone's effects on adenylate cyclase and the hexose monophosphate shunt. Arch Biochem Biophys 1977;184:69-76. (Pubitemid 8220793)
55. Dahlman I, Forsgren M, Sjögren A, Nordström EA, Kaaman M,Näslund E, et al. Downregulation of electron transport chain genes in visceral adipose tissue in type 2 diabetes independent of obesity and possibly involving tumor necrosis factor-alpha. Diabetes 2006;55:1792-9. (Pubitemid 44324134)
56. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008;223:7-19. (Pubitemid 351986171)
57. Iwanami K, Matsumoto I, Tanaka-Watanabe Y, Inoue A, Mihara M, Ohsugi Y, et al. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum 2008;58:754-63. (Pubitemid 351364873)
58. Matsumoto I, Zhang H, Yasukochi T, Iwanami K, Tanaka Y, Inoue A, et al. Therapeutic effects of antibodies to tumor necrosis factor-alpha, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis. Arthritis Res Ther 2008;10:R66.
59. Miot A, Maimaitiming S, Emery N, Bellili N, Roussel R, Tichet J, et al. DESIR Study Group. Genetic variability at the six transmembrane protein of prostate 2 locus and the metabolic syndrome: the data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. J Clin Endocrinol Metab 2010;95:2942-7.
60. Nanfang L, Yanying G, Hongmei W, Zhitao Y, Juhong Z, Ling Z, et al. Variations of six transmembrane epithelial antigen of prostate 4 (STEAP4) gene are associated with metabolic syndrome in a female Uygur general population. Arch Med Res 2010;41:449-56.
61. Wang Z-H, Zhang W, Gong H-P, Guo Z-X, Zhao J, Shang Y-Y, et al. Expression of STAMP2 in monocytes associates with cardiovascular alterations. Eur J Clin Invest 2010;40:490-6.
62. van Nimwegen MJ, van de Water B. Focal adhesion kinase: a potential target in cancer therapy. Biochem Pharmacol 2007;73: 597-609.
63. Li L, Li J, Shen Z, Liu W, Chen Z. [Clinical significance of six-transmembrane epithelial antigen of the prostate expressed in prostatic carcinoma]. Zhonghua Nan Ke Xue 2004;10:351-4.
64. Valenti MT, Dalle Carbonare L, Donatelli L, Bertoldo F, Giovanazzi B, Caliari F, et al. STEAP mRNA detection in serum of patients with solid tumours. Cancer Lett 2009;273:122-6.
65. Fleischhacker M. Biology of circulating mRNA: still more questions than answers? Ann N Y Acad Sci 2006;1075:40-9. (Pubitemid 44532763)
66. Zhou H, Xu W, Qian H, Yin Q, Zhu W, Yan Y. Circulating RNA as a novel tumor marker: an in vitro study of the origins and characteristics of extracellular RNA. Cancer Lett 2008;259:50-60. (Pubitemid 350235091)
67. Vaghjiani RJ, Talma S, Murphy CL. Six-transmembrane epithelial antigen of the prostate (STEAP1 and STEAP2)-differentially expressed by murine and human mesenchymal stem cells. Tissue Eng Part A 2009;15:2073-83.
68. Castillo AB, Jacobs CR. Mesenchymal stem cell mechanobiology. Curr Osteoporos Rep 2010;8:98-104.
69. Caillot F, Daveau R, Daveau M, Lubrano J, Saint-Auret G, Hiron M, et al. Down-regulated expression of the TSAP6 protein in liver is associated with a transition from cirrhosis to hepatocellular carcinoma. Histopathology 2009;54:319-27.
70. Coulouarn C, Derambure C, Lefebvre G, Daveau R, Hiron M, Scotte M, et al. Global gene repression in hepatocellular carcinoma and fetal liver, and suppression of dudulin-2 mRNA as a possible marker for the cirrhosis-to-tumor transition. J Hepatol 2005;42: 860-9. (Pubitemid 40693203)
71. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-46. (Pubitemid 35154440)
72. Yang D, Holt GE, Velders MP, Kwon ED, Kast WM. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res 2001; 61:5857-60. (Pubitemid 32769105)
73. Garcia-Hernandez MdeL, Gray A, Hubby B, Kast WM. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 2007;67:1344-51.
74. Kobayashi H, Nagato T, Sato K, Aoki N, Kimura S, Murakami M, et al. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner. Cancer Res 2007;67:5498-504. (Pubitemid 46997291)
75. Rodeberg DA, Nuss RA, Elsawa SF, Celis E. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin Cancer Res 2005;11:4545-52. (Pubitemid 40825645)
76. Alves PMS, Faure O, Graff-Dubois S, Cornet S, Bolonakis I, Gross D-A, et al. STEAP, a prostate tumor antigen, is a target of human CD8+ T cells. Cancer Immunol Immunother 2006;55:1515-23. (Pubitemid 44327839)
77. Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, et al. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res 2005;65:6435-42. (Pubitemid 40994432)
78. Azumi M, Kobayashi H, Aoki N, Sato K, Kimura S, Kakizaki H, et al. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer. J Urol 2010;183: 2036-44.
79. Behrens G, Li M, Smith CM, Belz GT, Mintern J, Carbone FR, et al. Helper T cells, dendritic cells and CTL Immunity. Immunol Cell Biol 2004;82:84-90. (Pubitemid 38388724)
80. Gray A, de la Luz Garcia-Hernandez M, van West M, Kanodia S, Hubby B, Kast WM. Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine 2009; 27[Suppl 6]:G52-9.
81. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 1995;52:459-67.
82. Hall RE, Birrell SN, Tilley WD, Sutherland RL. MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. Eur J Cancer 1994;30A:484-90. (Pubitemid 24171956)
83. Lapointe J, Labrie C. Role of the cyclin-dependent kinase inhibitor p27 (Kip1) in androgen-induced inhibition of CAMA-1 breast cancer cell proliferation. Endocrinology 2001;142:4331-8. (Pubitemid 32907061)
84. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990;50:5382-6. (Pubitemid 20302992)
85. Weijerman PC, Zhang Y, Shen J, Dubbink HJ, Romijn JC, Peehl DM, et al. Expression of prostatic factors measured by reverse transcription polymerase chain reaction in human papillomavirus type 18 deoxyribonucleic acid immortalized prostate cell lines. Urology 1998;51: 657-62. (Pubitemid 28186225)
86. Sramkoski RM, Pretlow TG, Giaconia JM, Pretlow TP, Schwartz S, Sy M-S, et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999;35:403-9. (Pubitemid 29380004)
87. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-25. (Pubitemid 37267805)